The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Arrowhead Pharmaceuticals 14-Day RSI Related Terms
ARWR vs CYTK, TECH, KRYS: 14-Day RSI Comparison
For the Biotechnology subindustry, Arrowhead Pharmaceuticals's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arrowhead Pharmaceuticals 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Arrowhead Pharmaceuticals's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arrowhead Pharmaceuticals (ARWR) has a 14-Day RSI of 43.61 as of Jul. 12, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Arrowhead Pharmaceuticals and its competitors. According to the industry distribution chart, Arrowhead Pharmaceuticals ranks #427 out of 1422 companies in the Biotechnology industry, placing it in the top 30%.
Is Arrowhead Pharmaceuticals' 14-Day RSI too high?
Arrowhead Pharmaceuticals' current 14-Day RSI is 43.61. The Biotechnology industry median 14-Day RSI is 49.08. Arrowhead Pharmaceuticals' value of 43.61 is 11.1% below this industry median. Based on the distribution chart, Arrowhead Pharmaceuticals ranks #427 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Arrowhead Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arrowhead Pharmaceuticals' 14-Day RSI compare to CYTK and TECH?
According to the Biotechnology industry distribution chart, Arrowhead Pharmaceuticals ranks #427 out of 1422 companies for 14-Day RSI. This puts Arrowhead Pharmaceuticals in the upper half of its industry. The industry median 14-Day RSI is 49.08. Arrowhead Pharmaceuticals' value of 43.61 is 11.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 49.08, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arrowhead Pharmaceuticals's current 14-Day RSI of 43.61 is 11.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Arrowhead Pharmaceuticals and its competitors. For the Biotechnology industry, the median 14-Day RSI is 49.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arrowhead Pharmaceuticals's current 14-Day RSI is 43.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arrowhead Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Arrowhead Pharmaceuticals (ARWR) is currently considered Significantly Overvalued. The stock's GF Value™ is $50.85, compared to a current price of $76.41 — trading 50.3% above its estimated fair value. The current 14-Day RSI is 43.61 and 11.1% below the Biotechnology industry median of 49.08. Arrowhead Pharmaceuticals' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Arrowhead Pharmaceuticals (ARWR), the current 14-Day RSI is 43.61 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arrowhead Pharmaceuticals (ARWR) Overvalued in 2026?
Based on GuruFocus' analysis, Arrowhead Pharmaceuticals stock appears to be overvalued.
The current stock price of $76.41 is trading 50.3% above its estimated GF Value™ of $50.85.
GuruFocus considers Arrowhead Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for ARWR:
14-Day RSI: 43.61
GF Value™: $50.85 vs. price of $76.41 (50.3% above fair value)
Industry Position: 11.1% below the Biotechnology median (#427 of 1422)
No single metric tells the full story. See the ARWR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
49GF Score
Get the complete analysis for ARWR
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARWR has been successfully added to your 